3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Advanced Breast Cancer
1
Interventions
Fulvestrant
19
Letrozole
10
Anastrozole
8
Capecitabine
5
palbociclib
4
olaparib
4
Paclitaxel
4
Injections
4
Goserelin
4
Docetaxel
4
trastuzumab deruxtecan
3
pyrotinib
3
exemestane
3
Vinorelbine
3
Aromatase Inhibitors
3
toripalimab
2
sacituzumab govitecan
2
ribociclib
2
eribulin
2
elacestrant
2
dalpiciclib
2
abemaciclib
2
Trastuzumab
2
Gonadotropin-Releasing Hormone
2
FCN-437c
2
Everolimus
2
Dasatinib
2
Alpelisib
2
Albumin-Bound Paclitaxel
2
AZD9833
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Breast Cancer
×
AZD5305
×
Breast
×
Clear all
NCT06380751
2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3
Recruiting
500 enrolled